Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
13.75
+0.47 (3.54%)
At close: Apr 28, 2026, 4:00 PM EDT
13.71
-0.04 (-0.29%)
After-hours: Apr 28, 2026, 4:04 PM EDT
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Enanta Pharmaceuticals stock have an average target of 20.4, with a low estimate of 12 and a high estimate of 28. The average target predicts an increase of 48.36% from the current stock price of 13.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Feb 10, 2026.
Analyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 4 | 4 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +45.45% | Feb 10, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +45.45% | Jan 9, 2026 |
| JP Morgan | JP Morgan | Buy Initiates $17 | Buy | Initiates | $17 | +23.64% | Nov 14, 2025 |
| WestPark Capital | WestPark Capital | Strong Buy Maintains $24 → $28 | Strong Buy | Maintains | $24 → $28 | +103.64% | Sep 30, 2025 |
| Evercore ISI Group | Evercore ISI Group | Buy Maintains $20 → $12 | Buy | Maintains | $20 → $12 | -12.73% | Sep 15, 2025 |
Financial Forecast
Revenue This Year
70.40M
from 65.32M
Increased by 7.76%
Revenue Next Year
66.99M
from 70.40M
Decreased by -4.83%
EPS This Year
-2.08
from -3.84
EPS Next Year
-1.93
from -2.08
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 78.1M | 79.7M | ||||||
| Avg | 70.4M | 67.0M | ||||||
| Low | 59.3M | 52.1M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 19.6% | 13.2% | ||||||
| Avg | 7.8% | -4.8% | ||||||
| Low | -9.1% | -26.0% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.38 | -1.59 | ||||||
| Avg | -2.08 | -1.93 | ||||||
| Low | -2.50 | -2.48 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.